title: Cytomegalovirus vaccination of leukemia and lymphoma patients after allogeneic stem cell transplantation--validation of a peptide vaccine.
abstract: Peptide vaccination constitutes a novel immunotherapeutical approach for the treatment of patients with solid tumors, lymphoma and leukemia. Moreover it might be of use in hematooncological patients for the prevention and therapy of infections like cytomegalovirus (CMV) reactivation due to immunosuppression. To meet good manufacturing practice (GMP) criteria, we introduce here a bio-assay to validate peptide vaccines for peptide content and bio-activity. As a paradigm for peptide vaccine preparation the immunogenic CMV peptide 495-503 NLVPMVATV lyophilisate was resolubilized in dimethyl sulfoxide, phosphate buffered saline and admixed with Montanide. Addition of different amounts of peptide (10-80 microg) to a mixed lymphocyte peptide culture (MLPC) resulted in the generation of interferon (IFN) gamma and granzyme B releasing CD8(+) CMV tetramer(+) T cells in a dose dependent manner. The combination of FACS and ELISPOT results allowed the definition of the peptide amount in a vaccine preparation. Storage at +/-4 degrees C over 24 h did not result in a significant change of the immunogenicity of the vaccine. In contrast, cryopreservation of the vaccine at -20 degrees C resulted in a loss of immunogenicity. Quantitation of tumor/viral antigen peptides admixed with adjuvants, such as incomplete Freund's adjuvant (IFA), is feasible through bio-assays as the modified ELISPOT/FACS assay described here, meeting GMP criteria for multi-center trials.
authors.affiliation: Department of Internal Medicine III, University of Ulm, Ulm, Germany.
authors.forename: Anita
authors.initials: A
authors.lastname: Schmitt
authors.forename: Clemens
authors.initials: C
authors.lastname: Bechter
authors.forename: Junxia
authors.initials: J
authors.lastname: Yao
authors.forename: Marlies
authors.initials: M
authors.lastname: Goetz
authors.forename: Birgit
authors.initials: B
authors.lastname: Maccari
authors.forename: Peter
authors.initials: P
authors.lastname: Schauwecker
authors.forename: Markus
authors.initials: M
authors.lastname: Wiesneth
authors.forename: Michael
authors.initials: M
authors.lastname: Schmitt
mesh_terms: D000956:Antigens, Viral / Q000032:analysis* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015925:Cryopreservation; D022482:Cytomegalovirus Vaccines / Q000276:immunology* / Q000592:standards; D004797:Enzyme-Linked Immunosorbent Assay; D053804:Granzymes / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D007938:Leukemia / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology*; D033581:Stem Cell Transplantation; D022223:Vaccines, Subunit / Q000276:immunology / Q000592:standards; D014614:Vaccines, Synthetic / Q000276:immunology / Q000592:standards
chemical_list: D000956:Antigens, Viral; D022482:Cytomegalovirus Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D007371:Interferon-gamma; D053804:Granzymes